AU2014257565A1 - Isolation of therapeutic target specific VNAR domains to ICOSL - Google Patents

Isolation of therapeutic target specific VNAR domains to ICOSL Download PDF

Info

Publication number
AU2014257565A1
AU2014257565A1 AU2014257565A AU2014257565A AU2014257565A1 AU 2014257565 A1 AU2014257565 A1 AU 2014257565A1 AU 2014257565 A AU2014257565 A AU 2014257565A AU 2014257565 A AU2014257565 A AU 2014257565A AU 2014257565 A1 AU2014257565 A1 AU 2014257565A1
Authority
AU
Australia
Prior art keywords
seq
icosl
antigen binding
specific antigen
vnar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014257565A
Other languages
English (en)
Inventor
Caroline Jane BARELLE
Alfredo DARMANIN-SHEEHAN
William James Jonathan Finlay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Aberdeen
Original Assignee
University of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Aberdeen filed Critical University of Aberdeen
Publication of AU2014257565A1 publication Critical patent/AU2014257565A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
AU2014257565A 2013-04-23 2014-04-23 Isolation of therapeutic target specific VNAR domains to ICOSL Abandoned AU2014257565A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361815043P 2013-04-23 2013-04-23
US61/815,043 2013-04-23
PCT/EP2014/058276 WO2014173975A1 (en) 2013-04-23 2014-04-23 Isolation of therapeutic target specific vnar domains to icosl

Publications (1)

Publication Number Publication Date
AU2014257565A1 true AU2014257565A1 (en) 2015-11-26

Family

ID=50543598

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014257549A Active AU2014257549B2 (en) 2013-04-23 2014-04-23 Synthetic library of specific binding molecules
AU2014257565A Abandoned AU2014257565A1 (en) 2013-04-23 2014-04-23 Isolation of therapeutic target specific VNAR domains to ICOSL
AU2019206064A Abandoned AU2019206064A1 (en) 2013-04-23 2019-07-18 Synthetic library of specific binding molecules

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2014257549A Active AU2014257549B2 (en) 2013-04-23 2014-04-23 Synthetic library of specific binding molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019206064A Abandoned AU2019206064A1 (en) 2013-04-23 2019-07-18 Synthetic library of specific binding molecules

Country Status (11)

Country Link
US (3) US10202438B2 (OSRAM)
EP (3) EP2989204B1 (OSRAM)
JP (2) JP6616284B2 (OSRAM)
KR (2) KR20160010466A (OSRAM)
CN (2) CN105492610B (OSRAM)
AU (3) AU2014257549B2 (OSRAM)
BR (2) BR112015026729A2 (OSRAM)
CA (2) CA2909921C (OSRAM)
DK (1) DK2989203T3 (OSRAM)
RU (2) RU2015146418A (OSRAM)
WO (2) WO2014173975A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130302250A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
KR20160010466A (ko) 2013-04-23 2016-01-27 더 유니버시티 코트 오브 더 유니버시티 오브 애버딘 Ｉｃｏｓｌ에 대한 치료학적 표적 특이적 ｖｎａｒ 도메인의 단리
WO2015200883A2 (en) * 2014-06-26 2015-12-30 Ossianix, Inc. Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
AU2015342264B2 (en) * 2014-11-03 2021-08-12 Merck Patent Gmbh Methods for generating bispecific shark variable antibody domains and use thereof
WO2016077840A2 (en) 2014-11-14 2016-05-19 Ossianix, Inc. TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
ITUB20151014A1 (it) * 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
CA3019199A1 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
CN107130300A (zh) * 2016-10-08 2017-09-05 深圳劲宇生物科技有限公司 一种dna编码分子库的合成方法及dna模板
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR102657978B1 (ko) * 2017-09-27 2024-04-16 엘라스모겐 리미티드 특이적 결합 분자
US11180544B2 (en) * 2017-11-07 2021-11-23 City University Of Hong Kong Method of producing antibody fragment
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
US12351642B2 (en) 2018-09-14 2025-07-08 Ossianix, Inc. TFR-specific binding moieties and transcytosis method to select VNARs that cross cellular barriers
CN111197074B (zh) * 2018-11-20 2023-08-15 深圳华大生命科学研究院 条纹斑竹鲨免疫球蛋白新抗原受体可变区库引物及应用
US20220130494A1 (en) * 2019-02-11 2022-04-28 Neal W. Woodbury Systems, methods, and media for molecule design using machine learning mechanisms
GB201906997D0 (en) * 2019-05-17 2019-07-03 Elasmogen Ltd Conjugates
GB201908886D0 (en) * 2019-06-20 2019-08-07 Almac Discovery Ltd Anthracycline derivatives
WO2021222546A1 (en) * 2020-05-01 2021-11-04 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for identifying nanobodies and nanobody affinities
CN112301431B (zh) * 2020-08-12 2023-01-31 华东理工大学 基于鲨鱼抗体可变区v-nar的噬菌体文库及其构建方法
GB202020154D0 (en) * 2020-12-18 2021-02-03 Almac Discovery Ltd ROR1-specific variant antigen binding molecules
GB202020152D0 (en) 2020-12-18 2021-02-03 Elasmogen Ltd Fast-track humanisation of specific binding molecules
WO2022212429A1 (en) * 2021-03-31 2022-10-06 Sachdev Sidhu Anti-viral compositions for rift valley fever virus infections and methods of using same
EP4141028A1 (en) 2021-08-31 2023-03-01 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars
GB202407865D0 (en) 2024-06-03 2024-07-17 Elasmogen Ltd Self immolative compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
DK1419179T3 (da) 2001-08-10 2010-06-21 Univ Aberdeen Antigenbindingsdomæner fra fisk
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
WO2005042743A2 (en) * 2003-08-18 2005-05-12 Medimmune, Inc. Humanization of antibodies
WO2005021719A2 (en) * 2003-08-27 2005-03-10 Proterec Ltd Libraries of recombinant chimeric proteins
DK2330121T3 (en) 2004-06-02 2014-12-15 Adalta Pty Ltd Binding moieties based on shark IgNar domains
EP1753783B1 (en) * 2004-06-03 2014-08-06 Novimmune SA Anti-cd3 antibodies and methods of use thereof
WO2006003999A1 (ja) * 2004-07-05 2006-01-12 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト抗ヒトb7rp-1抗体およびその抗体フラグメント
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
EP2368992A3 (en) * 2005-03-25 2012-03-14 National Research Council Of Canada Method for isolation of soluble polypeptides
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
CA2854576A1 (en) 2005-07-18 2007-01-25 Haichun Huang Human anti-b7rp1 neutralizing antibodies
CA2663042A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
JP2010505435A (ja) 2006-10-11 2010-02-25 アブリンクス エン．ヴェー． 本質的にｐＨに非依存的に血清タンパク質に結合するアミノ酸配列、それを含む化合物、およびその使用
WO2009026638A1 (en) 2007-08-31 2009-03-05 Melbourne Health Marine-animal derived therapeutic and diagnostic agents for hepatitis b
AU2009301631A1 (en) 2008-10-06 2010-04-15 Commonwealth Scientific And Industrial Research Organisation Amyloid-beta peptide crystal structure
AU2009301630A1 (en) * 2008-10-07 2010-04-15 Zap Holdings Limited Synchronization of relational databases with OLAP cubes
US8496933B2 (en) * 2009-11-04 2013-07-30 Laboratorios Silanes, S.A. De C.V. VHNAR anti-cytokine domains
US20140154241A1 (en) * 2010-12-03 2014-06-05 Cyclogenix Ltd Binding peptides i
US20130302250A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
CN103031304A (zh) * 2012-12-27 2013-04-10 苏州大学 一种微小rna用于调控b7-h2基因表达
KR20160010466A (ko) 2013-04-23 2016-01-27 더 유니버시티 코트 오브 더 유니버시티 오브 애버딘 Ｉｃｏｓｌ에 대한 치료학적 표적 특이적 ｖｎａｒ 도메인의 단리

Also Published As

Publication number Publication date
KR20160010466A (ko) 2016-01-27
US20200002403A1 (en) 2020-01-02
CA2909921A1 (en) 2014-10-30
JP2016524463A (ja) 2016-08-18
EP3683312A2 (en) 2020-07-22
KR102320189B1 (ko) 2021-11-03
US20160068600A1 (en) 2016-03-10
EP2989204B1 (en) 2019-03-20
AU2014257549B2 (en) 2019-04-18
CN105492610B (zh) 2020-08-25
US10472410B2 (en) 2019-11-12
US20160176951A1 (en) 2016-06-23
EP3683312A3 (en) 2020-09-16
EP2989203B1 (en) 2019-11-13
RU2015146418A (ru) 2017-05-26
JP6591964B2 (ja) 2019-10-16
US10202438B2 (en) 2019-02-12
EP3683312B1 (en) 2022-09-07
EP2989204A1 (en) 2016-03-02
RU2015146418A3 (OSRAM) 2018-05-07
KR20160015220A (ko) 2016-02-12
JP6616284B2 (ja) 2019-12-04
US11459377B2 (en) 2022-10-04
WO2014173975A1 (en) 2014-10-30
DK2989203T3 (da) 2020-02-17
JP2016524592A (ja) 2016-08-18
WO2014173959A2 (en) 2014-10-30
BR112015026716A2 (pt) 2017-09-05
AU2014257549A1 (en) 2015-11-26
CN105531370A (zh) 2016-04-27
CA2909921C (en) 2022-12-06
AU2019206064A1 (en) 2019-08-08
EP2989203A2 (en) 2016-03-02
WO2014173959A3 (en) 2015-01-29
RU2015146419A (ru) 2017-05-26
CN105492610A (zh) 2016-04-13
CA2909923A1 (en) 2014-10-30
BR112015026729A2 (pt) 2017-09-05

Similar Documents

Publication Publication Date Title
EP2989204B1 (en) Isolation of therapeutic target specific vnar domains to icosl
CN108473987B (zh) 具有改变的多样性支架结构域的结合成员
CN101115771B (zh) 人类抗体和蛋白质
EP4177267A1 (en) Anti-surrogate light chain antibodies
JP2021518168A (ja) 拮抗的抗原結合タンパク質
CN113614103A (zh) 不直接向其附着的细胞传导信号的非天然nkg2d受体
US20240376639A1 (en) Fast-track humanisation of specific binding molecules
CN116829584A (zh) 一种抗pd-1的单域抗体
CN120865416B (zh) 抗mica/b抗体及其应用
CN120865417B (zh) 抗mica/b抗体及其应用
HK40090806A (en) Anti-surrogate light chain antibodies
CN120865416A (zh) 抗mica/b抗体及其应用
HK40061399A (en) Non-natural nkg2d receptors that do not directly signal the cells to which they are attached

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted